Shockwave Medical (SWAV) Tops Q4 EPS, Revenue; Guides Above Views

Shockwave Medical (NASDAQ: SWAV) reported Q4 EPS of $3.71, which may not compare to the analyst estimate of $1.00. Revenue for the quarter came in at $144 million versus the consensus estimate of $142.66 million.

GUIDANCE:

Shockwave Medical sees FY2023 revenue of $660-680 million, versus the consensus of $658.58 million.

For earnings history and earnings-related data on Shockwave Medical (SWAV) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance